Welcome to our dedicated page for AUTOLUS THERAPEUTICS PLC news (Ticker: AUTL), a resource for investors and traders seeking the latest updates and insights on AUTOLUS THERAPEUTICS PLC stock.
Autolus Therapeutics plc (Nasdaq: AUTL) generates frequent news as an early commercial-stage biopharmaceutical company focused on next-generation programmed T cell therapies for cancer and autoimmune disease. News coverage for AUTL often centers on AUCATZYL® (obecabtagene autoleucel; obe-cel), the company’s CD19-directed CAR T cell therapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), and on the clinical and commercial progress of this product.
Investors and healthcare observers following Autolus news will see updates on AUCATZYL net product revenue, treatment center activation, and reimbursement developments such as NICE recommendations and conditional marketing authorizations in the UK and EU. Press releases also describe real-world data from consortia like ROCCA, which evaluate safety and response rates for AUCATZYL in clinical practice, alongside analyses from the FELIX study that explore CAR T-cell persistence and product cell phenotypes as potential predictors of long-term outcomes.
Autolus regularly reports clinical data from its broader pipeline, including the CATULUS trial in pediatric relapsed or refractory B-ALL, the CARLYSLE Phase 1 study in severe refractory systemic lupus erythematosus, the LUMINA Phase 2 trial in lupus nephritis and the BOBCAT trial in progressive multiple sclerosis. These updates typically highlight remission rates, safety profiles, B-cell depletion and immune reset signals in autoimmune indications. Additional news items cover collaborations, such as the evaluation of Cellares’ automated Cell Shuttle platform to support high-throughput CAR T manufacturing, and corporate developments including leadership appointments and participation in healthcare conferences.
This news page allows readers to track Autolus’ ongoing clinical milestones, regulatory and reimbursement decisions, manufacturing initiatives and financial disclosures related to its T cell therapy programs. For those monitoring AUTL, the flow of updates provides context on how AUCATZYL and pipeline candidates are progressing across hematologic malignancies, solid tumors and autoimmune diseases.
Pyramid Biosciences has appointed Dr. Nushmia Khokhar as the new Chief Medical Officer to lead the company's clinical pipeline advancements. Dr. Khokhar, previously with Umoja Biopharma and Autolus Therapeutics, brings extensive experience in oncology clinical development. The CEO, Brian Lestini, expressed confidence in her leadership during this growth phase. Dr. Khokhar's background includes significant roles at Johnson & Johnson, where she directed successful clinical trials for cancer therapies. Pyramid Biosciences focuses on creating precision therapies for serious diseases.
Autolus Therapeutics announced its Q2 2022 operational and financial results, highlighting significant advancements in its clinical pipeline. The company received RMAT designation from the FDA for obe-cel in April 2022 and continues to progress in the pivotal Phase 2 FELIX trial for r/r ALL. Financially, Autolus reported a net loss of $42.1 million and operating expenses of $46.5 million for the quarter. Cash reserves decreased to $216.4 million, extending the runway into 2024. Initial results from the FELIX trial are anticipated in Q4 2022.
Autolus Therapeutics plc (Nasdaq: AUTL) will release its second quarter 2022 financial results and operational highlights before the U.S. market opens on August 4, 2022. A conference call and webcast will be held at 8:30 am ET/1:30 pm BST to discuss these results and provide a business update. Participants must pre-register to receive dial-in information. The webcast will also be available for replay in the events section of Autolus' website.
Autolus Therapeutics plc (Nasdaq: AUTL) will announce its Q2 2022 financial results and operational highlights on August 4, 2022, prior to the U.S. market opening. A conference call and webcast featuring management will occur at 8:30 am ET to discuss the results and provide an update on the company's business. Participants can pre-register for the call to receive dial-in numbers and PINs. The audio webcast will also be accessible on the company's website.
Autolus Therapeutics (Nasdaq: AUTL) announced its participation in William Blair’s Biotech Focus Conference 2022 in New York City on July 12. CEO Dr. Christian Itin will join a panel discussion titled ‘Operationalizing Cell Therapies’ from 8:55 to 10:15 am ET. The company aims to advance next-generation programmed T cell therapies for cancer treatment. With proprietary technologies, Autolus develops targeted T cell therapies designed to combat various cancers, focusing on hematological malignancies and solid tumors.
Autolus Therapeutics (Nasdaq: AUTL) announced significant clinical data at the European Hematology Association Congress from June 9-12, 2022. Key highlights include:
- AUTO4: Shows promising activity for T cell lymphoma with favorable safety profiles.
- AUTO1/22: Demonstrates strong remission rates in children with B-ALL, even those unresponsive to existing CAR T therapies.
- Obe-cel: Exhibits sustained efficacy in B-NHL and emerging activity in Primary CNS Lymphoma.
A conference call will take place on June 13, 2022, at 7:30 AM EST to discuss these findings.
Autolus Therapeutics plc (Nasdaq: AUTL) has announced its Annual General Meeting (AGM) to be held on June 28, 2022, in London. The official notice for shareholders details the meeting's agenda, which includes ordinary and special resolutions. The company will announce the results of the voting via a press release following the AGM. Autolus is focused on developing advanced T cell therapies for cancer treatment, utilizing proprietary technologies to create targeted therapies aimed at hematological malignancies and solid tumors.
Autolus Therapeutics plc (Nasdaq: AUTL) announced participation in the Jefferies Healthcare Conference in New York City on June 9, 2022. CEO Dr. Christian Itin will engage in a Fireside Chat from 9:00 to 9:30 am ET. The company will also hold one-on-one investor meetings at the event. An audio webcast of the Fireside Chat will be available on Autolus' website, with an archived version accessible for a limited period post-conference. Autolus specializes in programmed T cell therapies aimed at treating various cancers.
Autolus Therapeutics (AUTL) has announced the online publication of four abstracts for the European Hematology Association (EHA) Congress, scheduled for June 9-12, 2022. Notable presentations include early clinical data for AUTO4 targeting peripheral T cell lymphoma and AUTO1/22 for pediatric B-cell acute lymphoblastic leukemia. CEO Christian Itin expressed optimism about the early safety and efficacy data, particularly for the lead asset, obe-cel. A conference call on June 13, 2022, will detail these findings and propose next steps for the pipeline.
Autolus Therapeutics (NASDAQ: AUTL) reported operational and financial results for Q1 2022, revealing a net loss of $37.1 million, or $(0.41) per share. Cash reserves decreased to $268.6 million from $310.3 million as of December 31, 2021. Significant updates include the successful futility analysis of the FELIX clinical trial for obe-cel in adult B-cell Acute Lymphoblastic Leukemia, which received RMAT designation from the FDA. Initial data from the trial is expected in late 2022. Autolus also continues its pipeline developments, with upcoming presentations at the EHA Congress in June.